Clinical trials: Treatment Resistant Major Depression Disorder
Major Depression
Antidepressant Effects of NR2B in Major Depression
Purpose : This study will determine whether MK-0657, a selective NR2B Antagonist, can quickly improve symptoms of depressed mood, psychomotor retardation, poor motivation and reduced enjoyment of things in patients with major…
- Trial name
- NCT00472576
- Testing
- MK-0657
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- SAINT-TRD (NCT03240692)
- Testing
- Accelerated theta-burst stimulation treatment
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Stanford University
Treatment Resistant Depression, Major Depressive Disorder
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression
- Trial name
- OPTIMUM (NCT02960763)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion
- Where
- 5 sites in United States, Canada
- Volunteers
- 742 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression
Electroconvulsive therapy (ECT), is considered the most effective treatment for severe treatment resistant major depressive disorder (MDD), but it requires about 3 weeks of treatments and can cause considerable acute deficits in…
- Trial name
- NCT01260649
- Testing
- ketamine, IV Saline, ECT
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
The purpose of this study is to see if adding the study drug, ziprasidone, to an antidepressant medication helps improve symptoms of Major Depressive Disorder (MDD).
- Trial name
- NCT00633399
- Testing
- Ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 458 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Optimization of IV Ketamine for Treatment Resistant Depression
Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD.
- Trial name
- NCT00768430
- Testing
- Ketamine, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Baylor College of Medicine